The cerebrospinal fluid fractalkine as a biomarker in mild cognitive impairment (MCI): Biomarkers (non‐neuroimaging) / novel biomarkers. (7th December 2020)

• Record Type: Journal Article
• Authors: Mroczko, Barbara; Kulczynska‐Przybik, Agnieszka; Klimkowicz‐Mrowiec, Aleksandra; Pera, Joanna; Borawska, Renata; Muszynski, Pawel; Mroczko, Piotr; Dulewicz, Maciej; Slowik, Agnieszka
• Is Part Of: Alzheimer's & dementia. Volume 16(2020)Supplement 4
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-12-07
• Subjects: Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.039731
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: Mild cognitive impairment (MCI) is a neurological disorder that occurs in older adults and could be a very early phase of AD dementia. It is not only medical but also socioeconomic and legal problem. Since the MCI symptoms are not yet associated with such serious memory problems as in dementia, it may be difficult to assess the patient's legal capacity. This is an extremely important issue, among others, from the point of view of the patient's decision about his/her treatment process. His ability to fully understand his health situation and the ability to make rational decisions, including being aware of its effects, can be difficult to assess, which has significant legal effects. Therefore, the biomarkers of early stage of dementia are critically important. Growing body of evidence indicated that overexpression of CX3CL‐1 may influence on tau pathology and modulate the dementia disorders development. In our investigation we aim to measure the cerebrospinal fluid concentration of fractalkine to assess the potential usefulness of this protein in the diagnosis of MCI patients. Moreover, the CSF CX3CL‐1 level was compared to the concentrations of classical AD biomarkers, including Aβ‐42, Aβ‐42/Aβ‐40, tau and pTau181. Method: The study included 18 patients with MCI and 18 non‐demented controls. The cerebrospinal fluid levels of CX3CL‐1 and classical AD biomarkers, such as Aβ‐42, Aβ‐42/Aβ‐40, tau and pTau181, were assessed by immunoenzyme assays. Result: The concentration of fractalkine was significantly higher in cerebrospinal fluid of MCI patients when compared to non‐demented controls. The increased CSF levels of CX3CL‐1 were observed to significantly correlate with amyloid beta 1‐42 (Aβ‐42) and phosphorylated tau protein (pTau181) in mild cognitive impairment MCI subjects. Moreover, similar association between CX3CL‐1 concentrations and Aβ‐42/Aβ‐40 ratio was revealed in the control group. Conclusion: Presented findings indicate a potential role of CX3CL‐1 in the pathology of MCI and possible usefulness of this protein in the early diagnosis of patients with cognitive impairment. The study was conducted with the use of equipment purchased by Medical University of Białystok as part of the RPOWP 2007‐2013 funding, Priority I, Axis 1.1, contract No. UDA‐RPPD.01.01.00‐20‐001/15‐00 dated 26.06.2015.